natgillin/translations-raw huggingface dataset:
The compounds of the invention, and their pharmaceutically acceptable salts, thereby provide methods of treatment of AB-related pathologies, such as, but not limited to, Alzheimer's disease, Down's syndrome, B-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI (“mild cognitive impairment”), memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy traumatic brain injury and cortical basal degeneration. 
Spoj ili njegova farmaceutski prihvatljiva sol u skladu sa zahtjevom 1 naznačen time da je za uporabu u postupku liječenja ili prevencije AB-povezane patologije, pri čemu navedena Af3-povezana patologija je Downov sindrom, familoidna angiopatija, cerebralna amiloidna angiopatija, nasljedno cerebralno krvarenje, poremećaj povezan s kognitivnim poremećajem, MCI ("blagi kognitivni poremećaj"), Alzheimerova bolest, gubitak pamćenja, simptomi poremećaja pažnje povezani s Alzheimerovom bolesti, neurodegeneracija povezana s Alzheimerovom bolesti, demencija miješanog vaskularnog podrijetla, demencija degenerativnog porijekla, presenilna demencija, senilna demencija, demencija povezana s Parkinsonovom bolesti, progresivna supranuklearna paraliza i kortikobazalna degeneracija.
1HNMR spectra were obtained at 400 MHz on a Bruker-Spectrospin Ultrashield 400 spectrophotometer. 
Spektri 'H-NMR dobiveni su na 400 MHz, na spektrofotometru Bruker-Spectrospin Ultrashield 400.
The thread heights for the preferred connection of the invention will typically be greater than the prior art. The average thread height of the pin treads will tend to be about 0.04 inches, or greater. 
2.,Make and break" priključak s navojem iz zahtjeva 1, naznačen time da je prosječna visina navoja (hl, h2, h3, h4) klinastih navoja oko 0,04 inčeva ili veća.
A method of preparing a compound according to claim 1, comprising reacting an intermediate compound of formula (A5), (B5) or (C5): 
Postupak za dobivanje spoja prema zahtjevu 1, naznačen time da navedeni postupak sadrži korak pretvaranja intermedijarnog spoja s formulom (B5):
The pharmaceutical composition according to claim 21, wherein said additional agent is a CFTR modulator other than a compound of Formula (I). 
Farmaceutski pripravak prema zahtjevu 21, naznačen time da je navedeno dodatno sredstvo CFTR modulator koji je različit od spoja sa formulom (1).
the pharmaceutical composition for oral administration of [1] or [2], wherein 70% or more of solifenacin is dissolved for 15 minutes; 
Tableta za oralnu primjenu prema zahtjevu 1 ili 2, gdje se 65% ili više solifenacina otpušta nakon 15 minuta.
wherein the discharge orifice (19) has a diameter of 0.15 to 0.65 mm and a length of 0.5 to 1.0 mm; wherein the maximum transverse dimension of the transfer channel (13) is from 1.0 to 3.0 mm; 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je maksimalna transverzalna dimenzija prijenosnog kanala (13) veća od promjera ispusnog otvora (19).
"acyl", as used herein, pertains to a -C(=O)R group, wherein R is H, a C1-7 alkyl group, a C3-20 heterocyclyl group, or a C5-20 aryl group; 
"acil", kako se ovdje koristi, odnosi se na -C(=0)R skupinu, pri čemu R je H, Ci; alkilna skupina, C3.20 heterociklilna skupina, ili C5. arilna skupina;
An absorbent composition, suitable for removing mercury, arsenic or antimony from a fluid stream, comprising 5-50% by weight of a particulate sulphided copper compound and 30-90% by weight of a particulate support material selected from an alumina, hydrated alumina, titania, zirconia, silica or aluminosilicate, or a mixture of two or more of these, and the remainder one or more binders comprising a first binder and a second binder, wherein the first binder is a calcium aluminate cement binder and the second binder is a high aspect ratio aluminosilicate clay binder having an aspect ratio >2, and wherein the metal sulphide content of the absorbent, other than copper sulphide, is ≤ 5% by weight. 
PATENTNI ZAHTJEVI Apsorbentna mješavina, pogodna za uklanjanje žive, arsena ili antimona iz struje fluida, naznačena time što sadrži 5-50%, težinski, partikularnog sulfidiranog bakrenog spoja i 30-90%, težinski, partikularnog nosivog materijala, kojeg se bira između aluminijevog oksida, hidratiranog aluminijevog oksida, titanijevog dioksida, cirkonijevog dioksida, silicijevog dioksida ili alumosilikata, ili smjesu iz dva ili više od navedenih, gdje je ostatak jedno ili više veziva koja uključuju prvo vezivo i drugo vezivo, gdje je prvo vezivo kalcijev aluminatni cement kao vezivo, a drugo je vezivo alumosilikatna glina visokog omjera dimenzija kao vezivo s omjerom dimenzija >2, te gdje je sadržaj metalnog sulfida u apsorbensu, koji nije bakreni sulfid, < 5%, težinski.
R1b is an optionally substituted phenyl or heteroaryl wherein optional substituents can be selected from one or more of alkyl, cycloalkyl, halo, alkoxy, trifluoroalkyl, or aryl; and 
R, je vodik, po izboru supstituirani alkil, alkenil, alkinil, cikloalkil, aril, heterociklil, heteroaril, aralkil, alkoksi, ariloksi, alkeniloksi ili alkiniloksi.
The resulting sulfonyl esters can be transformed into compounds X under the conditions discussed for compounds XVII followed by cleavage of the silyl protective group by methods known to the persons skilled in the art and detailed in the textbook Protective Groups in Organic Synthesis, Greene and Wuts, Wiley Interscience, (1991), ISBN 0471623016. 
Dobiveni sulfonil esteri mogu se transformirati u spojeve X u uvjetima navedenima za spojeve XVII i potom cijepanjem sililne zaštitne grupe na načine poznate struci i opisane u udžbeniku Protective Groups In Organic Synthesis, Green i Wuts, Wiley Interscience, (1991), ISBN 0471623016.
introducing to said water a coagulation agent consisting in an aqueous solution of polysaccharide microgels with a molecular mass of 20,000-200,000 Da and a particle size of 50-600 nm, said solution having a concentration of microgels not lower than 0.1 g/l. so that after this treatment said suspended particles of oil or oil products become coated with a thin polysaccharide film; 
uvođenje u spomenutu vodu agensa koagulacije sastojeći se od vodene otopine polisaharidnih mikrogelova s molekularnom masom od 20.000 do 200.000 Da i veličinom čestice od 50 do 600 nm, spomenuta otopina imajući koncentraciju mikrogelova koja nije manja od 0.1g/l, tako da nakon tretmana spomenute lebdeće čestice nafte ili naftnih proizvoda bivaju premazane tankom polisaharidnom opnom;
A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of claim 1, and at least one pharmaceutically acceptable carrier. 
Farmaceutski sastav koji se + iz spoja ili farmaceutski prihvatljive soli iz patentnog zahtjeva 1 i najmanje jednog farmaceutski prihvatljivog nosača.
In the context of the present invention, it is envisaged to sensitize tumor cells of any cell type or to treat any tumorigenic disease. Preferably, the tumor cells or the tumorigenic disease are of a type selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, medulloblastoma, melanoma, pancreatic cancer, prostate carcinoma, head and neck cancer, breast cancer, lung cancer, ovarian cancer, endometrial cancer, renal cancer, neuroblastomas, squamous cell carcinomas, medulloblastomas, hepatoma, colon cancer, and mesothelioma and epidermoid carcinoma. 
Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 4 do 11, naznačena time što tumorske stanice ili tumorogena bolest su tipa koji se bira iz skupine koju čine astrocitom, oligodendrogliom, meningiom, neurofibrom, glioblastom, ependimom, Schwannom, neurofibrosarkom, meduloblastom, melanom, rak gušterače, karcinom prostate, rak glave i vrata, rak dojke, rak pluća, rak jajnika, rak endometrija, rak bubrega, neuroblastomi, karcinomi pločastih stanica, hepatom, rak debelog crijeva i mezoteliom i epidermoidni karcinom, ili, što su tumorske stanice iz tumora epitela ili što je tumorogena bolest tumor epitela.
On the basis of the number of conditioned responses (avoidances), the dose of product capable of reducing the value of this variable by 50% (ED50) compared to basal values was calculated by means of non-linear regression using the GraphPad Prism data analysis program. 
Na osnovu broja uvjetovanih odgovora (izbjegavanja), izračunata je doza produkta koja je mogla reducirati vrijednost ove varijable 50 % (EDs0) u usporedbi s osnovnim vrijednostima pomoću nelinearne regresije koristeći GraphPad Prism program za analizu podataka.
A continuous and diploid duck cell line according to claim 1, wherein said virus is selected from the group comprising poxviruses, orthomyxoviruses, paramyxoviruses, herpes viruses, hepadnaviruses, adenoviruses, parvoviruses, reoviruses, circoviruses, coronaviruses, flaviviruses, togaviruses, birnavriruses and retroviruses. 
Postupak prema zahtjevu 10, gdje se taj virus izabire iz grupe koja obuhvaća pox viruse, ortomiksoviruse, paramiksoviruse, herpes viruse, hepa dna viruse, adenoviruse, parvoviruses, reoviruse, cirkoviruse, koronaviruse, flaviviruse, togaviruse, birnaviruse i retroviruse.
The transmitter of paragraph 10, wherein the length of the data slice ID information is 8 bits. 
Predajnik iz patentnog zahtjeva 10, pri čemu duljina ID informacije podatkovnog reza iznosi 8 bitova.
is aryl, C3-C12 cycloalkyl or heterocyclyl each optionally substituted by one or more hydroxy, oxo, halogen, amino, lower alkyl-amino, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower alkoxy), lower alkoxy (optionally substituted at one or more positions by halogen or hydroxy), carboxy, carbonylalkoxy, carbamoyl, carbamoylalkyl, aryl, aryloxy, arylalkoxy or heterocyclyl; 
je aril, C3-C12 cikloalkil ili heterociklil svaki proizvoljno supstituiran sa jednim ili više hidroksi, okso, halogenom, amino, nižim alkil-amino, alkilom (proizvoljno supstituiranim u jednom ili više položaja sa halogenom, hidroksi ili nižim alkoksi), nižim alkoksi (proizvoljno supstituiranim u jednom ili više položaja sa halogenom ili hidroksi), karboksi, karbonilalkoksi, karbamoil, karbamoilalkilom, arilom, ariloksi, arilalkoksi ili heterociklilom;
Het16 represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl, 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C1-4alkyl; 
Het16 predstavlja heterocikal odabran od morfolinil, pirolidinil, piperazinil, 1,3,2-dioksaborolan ili piperidinil pri čemu navedeni heterocikal je proizvoljno supstituiran sa jednim ili više supstituenata odabranih iz skupine koja sadrži C1-4alkil;
The formulation according to claim 1, wherein at least 80% of the vWF binder retains its binding activity after 12 months of storage at a temperature of −70° C. to +25° C. compared to the binding activity prior to storage, said binding activity as measured by ELISA and/or surface plasmon resonance (SPR). 
Formulacija prema bilo kojem od zahtjeva 1-6, naznačena time što najmanje 80%, poželjno najmanje 90%, poželjnije najmanje 95% ili čak najmanje 99% vWF veziva zadržava svoju aktivnost vezanja nakon skladištenja u usporedbi sa aktivnosti vezanja prije skladištenja, navedena aktivnost vezanja mjerena je pomoću testa ELISA i/ili Biacore.
Binding experiments are performed in buffer containing 10 mM HEPES, 150 mM NaCl, and 0.1% BSA, pH=7.5. 
Eksperimenti s vezanjem provedeni su u puferu koji sadrži 10 mM HEPES, 150 mM NaCI 1 0,1 % BSA, pH 7,5.
A process according to claims I to 4 wherein step c/n is carried out by reacting a compound of formula IIIa or IIIb with 9-borabicyclo[3.3.1]nonane to give a compound of formula IVa or IVb in the form of diastereomeric mixture. 
Postupak prema zahtjevima 1 do 4, naznačen time da se koraci c/n provode reakcijom smjese formule IIIa ili IIIb s 9-borabiciklo[3.3.1]nonanom, da bi se dobio spoj formule TVa ili IVb u obliku dijasteromer smjese.
The smoking article of the present invention will be further illustrated with reference to the following example which aids in the understanding of the present invention, but which are not to be construed as limitations thereof. 
Cigaretni substitut iz sadašnjeg izuma će biti dalje ilustriran imajući za referencu slijedeće primjere koji pomažu razumijevanju sadašnjeg izuma, ali koje ne treba shvatiti kao njegovo ograničenje.
The antibody, or antigen-binding fragment thereof, of Claim 1, comprising an LCVR and an HCVR, wherein the LCVR is the polypeptide of SEQ ID NO: 9, and the HCVR is the polypeptide of SEQ ID NO: 10 or SEQ ID NO: 11. 
Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1, naznačeno time što sadrži LCVR i HCVR, gdje je LCVR polipeptid sa slijedom SEQ ID NO: 9, a HCVR je polipeptid sa slijedom SEQ ID NO: 10 ili SEQ ID NO: 11.
Thus behaviour in the acquisition phase of the test (and locomotor activity) is unaffected by PCP treatment. 
Tako ponašanje u usvajajućoj fazi testa (lokomotorna aktivnost) nije zahvaćeno PCP tretiranjem.
Furthermore, said additional feature of the package, which may incorporate a cut-out, provides a possibility of visual presentation of the content of the box. 
Nadalje, navedena dodatna karakteristika pakiranja, mogući otvor na istoj, omogućuje vizualno prezentiranje sadržaja kutije.
Cholesterol levels were measured at the 24-hour trough level on day 11, Results (Figure 9) indicate that rats treated with rapamycin displayed significantly increased levels of cholesterol relative to a vehicle control group, while cholesterol levels in the 42-O-(D-fructosylcarbonyl)rapamycin group were significantly lower (p < 0.01) than in the rapamycin group and not significantly different than the vehicle. 
Razine kolesterola mjerene su tijekom 24 sata 11. dana. Rezultati (slika 9) pokazuju da štakori tretirani rapamicinom pokazuju značajno povišene razine kolesterola u usporedbi s kontrolnom grupom, dok su razine kolesterola u grupi 42-O-(D-fruktozilkarbonil)rapamicina bile značajno niže (p < 0,01) nego u rapamicinskoj grupi, a ne značajno različite od nosača.
A beverage preparation machine (1) according to claim 8, wherein the display is a LED lamp, a synthetic voice message, a screen which displays a written message to the user, or a combination thereof. 
Stroj za pripravu napitaka (1) u skladu s patentnim zahtjevom 8, naznačen time što je prikazivač LED svjetiljka, poruka umjetnim glasom, ekran koji prikazuje pisanu poruku za korisnika, ili njihova kombinacija.
wherein said cover part comprises denesting means (13,13') near the end surfaces near the top surface of the cover part wherein said denesting means comprises an abutment surface (18) below the top surface next to an end surface, characterised in that abutment surface comprises a thickened part of said front and/or rear surface (8) and connecting to said top surface (7). 
pri čemu navedeni dio koji predstavlja poklopac ima sredstva za odvajanje (13, 13 ́) u blizini krajnjih ploha i u blizini gornje plohe dijela koji predstavlja poklopac, pri čemu navedena sredstva za odvajanje imaju plohu za nalijeganje (18) koja se nalazi ispod navedene gornje plohe uz krajnju plohu, naznačena time što navedena ploha za nalijeganje ima jedan podebljani dio navedene prednje plohe i/ili stražnje plohe (8) i povezana je s navedenom gornjom plohom (7).
and extracted with methylene chloride (250 ml. 
i ekstrahira se sa metilenkloridom (250 ml.
The method of claim 8, wherein the pharmaceutical composition is in the form of a lyophilized powder or a frozen solution. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 12, naznačen time što je u obliku liofiliziranog praha ili smrznute otopine.
An aqueous pharmaceutical formulation with pH between 3.4 and 4.6 comprising insulin glargine for use in providing a peakless long acting basal insulin in the treatment of Type I and Type II Diabetes Mellitus in a patient, wherein the concentration of insulin glargine is 200-500 U/mL being equimolar to 200-500 IU human insulin. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za osiguravanje dugodjelujućeg bazalnog inzulina bez vrhunca u liječenju dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
3 shows a partial view of the extraction module in an open state, 
Slika 3 prikazuje djelomičan pogled na modul za ekstrakciju u otvorenom položaju,
The compound was purified on a YMC silica column to yield the compound of Formula 24. 
Spoj je bio očišćen na YMC stupcu silicija da bi se dobio spoj formule 24.
The preparation according to the Claim 1 characterized in that, it contains 0.1 to 2.5 mass% of histaminase, 0.1 to 2.5 mass% of catalase and 0.5 to 3.2 mass% of protease inhibitor calculated to dry material. 
Pripravak prema zahtjevu 1, naznačen time da sadrži 0,1 do 2,5 masena % histaminaze, 0,1 do 2,5 masena postotka katalaze i 0,5 do 3,2 masena postotka inhibitora proteaze, računato na suhu supstanciju.
The New Methylene Blue can be present in amounts sufficient to achieve about 735 uM under staining conditions. 
Novo metilensko modrilo prisutno u dovoljnoj količini da se dobiju koncentracije od oko 735 uM u uvjetima bojenja;
It comes from the hydrolysis of ET-743 and has the following structure: 
Nastaje hidrolizom ET-743 i ima sljedeću strukturu:
determiningtransform coefficients from the unpacked and decoded frequency domain exponent and mantissa data; 
određivanje transformacijskih koeficijenata (605) iz raspakiranog i dekodiranog eksponenta frekvencijske domene i podataka o mantisi;
It has been found that the method of sampling described above is more comfortable for the women. 
Ustanovilo se da je ovaj postupak uzimanja uzorka, koji je gore opisan, mnogo udobniji za ženu.
An isolated IL-23p19 antibody fragment, comprising a light chain variable region comprising: a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:9; 
CDRH2 sekvencu aminokiselina SEQ ID NO: 15; 1 CDRH3 sekvencu aminokiselina SEQ ID NO: 16; ili (11) navedena varijabilna regija laganog lanca sadrži:
Formula XXXIII. The compound of Formula XXXIII can be oxidatively cleaved to form a compound of Formula XXXIV. 
R, Formula XVI hidrogeniranje spoja Formule XVI, čime se dobiva spoj Formule XVII:
said formulation including an inorganic or organic filler, in an amount less than 20% by weight, preferably less than 10% by weight, still more preferably said formulation not including any inorganic or organic filler. 
gdje navedena formulacija sadrži anorgansko ili organsko punilo, u količini manjoj od 10%, težinski, još poželjnije gdje navedena formulacija uopće ne sadrži anorgansko ili organsko punilo.
Ion-mobility spectrometer according to Claim 6 or 7, characterized in that the pre-filter (14) comprises 3 - 11, preferably 5 - 9 part channels. 
Ionski mobilni spektrometar sukladno zahtjevu 6 ili 7, naznačen time, da prethodni filter (14) sadrži 3-11, poželjno 5-9 parcijalnih kanala.
Ar can also represent a pyridine group. Ar may notably be selected from the following groups: 
Spoj prema patentnom zahtjevu 5, naznačeno time da Ar predstavlja skupinu odabranu od sljedećih skupina:
Device according to item 32, wherein the device contains a quantity of vaccine formulation for a single intranasal or inhalational administration. 
Naprava prema patentnom zahtjevu 13, naznačena time da naprava sadrži količinu formulacije cjepiva za jedno intranazalno ili inhalacijsko davanje.
A compound as defined in any of claims 1-14, for use in the treatment of melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, sarcoma, liver cancer, biliary tract cancer, cholangiocarcinoma, colorectal cancer, lung cancer, gallbladder cancer, breast cancer, pancreatic cancer, thyroid cancer, renal cancer, ovarian cancer, adrenocortical cancer, prostate cancer, histiocytic lymphoma, neurofibromatosis, gastrointestinal stromal tumors, acute myeloid leukemia, myelodysplastic syndrome, leukemia, tumor angiogenesis, medullary thyroid cancer, carcinoid, small cell lung cancer, Kaposi's sarcoma, pheochromocytoma, acute pain, chronic pain, or polycystic kidney disease. 
Spoj kako je definiran u bilo kojem od zahtjeva 1-14, naznačen time da je za uporabu za liječenje melanoma, glioma, glioblastoma multiforme, pilocitnog astrocitoma, sarkoma, raka jetre, raka žučnog trakta, kolangiokarcinoma, raka debelog crijeva, raka pluća, raka žučnog mjehura, raka dojke, raka gušterače, raka štitnjače, raka bubrega, rak jajnika, raka nadbubrežne žlijezde, rak prostate, histiocitnog limfoma, neurofibromatoze, gastrointestinalnih stromalnih tumora, akutne mijeloidne leukemije, mijelodisplastičnog sindroma, leukemije, tumorske angiogeneze, medularnog karcinoma štitnjače, karcinoida, raka pluća malih stanica, Kaposijevog sarkoma, feokromocitoma, akutne boli, kronične boli, 1li policistične bolesti bubrega.
In such a condition, the stem of the rivet (8) is adapted to alternatively slide along the half moon shaped slot (4 a) of the second arm (4), from one end to the other, according to the rotation direction given by said lever mechanism (L) provided in the device of the invention. 
Zglobni držač prozorskog kapka prema jednom ili više prethodnih zahtjeva, naznačen time da spomenuti drugi krak (4) na jednom od svojih uzdužnih rubova a u blizini spomenute četvrte okretne osovinice (P4), ima jednu izbočinu (4c) koja strši prema dolje, malo ispod debljine tog drugog kraka (4); pri tom je predviđeno da spomenuta
The present invention relates to a compound of Formula I: 
HR P20160545 T1 PATENTNI ZAHTJEVI Spoj s formulom I:
Such atomisers are described, for example, in PCT Patent Application No. 
Takvi su atomizatori opisani, primjerice, u PCT patentnoj prijavi br.
The kit of claim 1, wherein the kit includes all of the foods to be ingested by the subject the day before the medical procedure. 
Komplet iz patentnog zahtjeva 1, pri tome taj komplet sadrži svu hranu koju pacijent treba progutati dan prije medicinskog postupka.
The method as recited in Clause 19 wherein said additional therapeutic agent is selected from the group consisting of olanzapine and pimozide. 
Spoj za uporabu prema zahtjevu 5, naznačen time da se navedeno dodatno terapijsko sredstvo bira iz skupine koju čine olanzapin i pimozid.
a solid form comprising the enantiomerically pure compound of formula (I): which has an X-ray powder diffraction pattern comprising peaks at about 7.6, 9.2, 11.4, 17.9 and 26.6 degrees 2θ; 
čvrstog oblika koji sadrži enantiomerno čisti spoj formule (I): [image], čiji uzorak difrakcije rendgenskih zraka na prahu sadrži signale na otprilike 7,6, 9,2, 11,4, 17,9 i 26,6 stupnjeva 2θ;
A method of treating adhesive capsulitis in a subject in need of such treatment comprising delivering an effective amount of collagenase to collagenous adhesions in the shoulder, wherein the collagenase is obtained from Clostridium histolyticum, wherein the subject is a human patient and wherein the method comprises injecting collagenase to the patient in a dose of about 10,000 ABC units. 
Uporaba kolagenaze za proizvodnju lijeka za liječenje adhezivnog kapsulitisa kod subjekta koji je čovjek kojem treba takvo liječenje, naznačena time da se navedeni pripravak dostavlja u kolagene adhezije u ramenu pri čemu se kolagenaza dobiva od iz soja bakterija Clostridium histolyticum, te pri čemu se u razmaku od 4 do 6 tjedana daju najmanje dvije injekcije od najmanje 700 SRC jedinica kolagenaze.
The nutrition according to any of the preceding claims further comprising eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA), and/or arachidonic acid (ARA). 
Hrana u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što nadalje sadrži eikosapentaensku kiselinu (EPA) i/ili dokozaheksaensku kiselinu (DHA) i/ili arahidonsku kiselinu (ARA).